984 results on '"Oba, Koji"'
Search Results
152. Focused Assessment with Sonography for Trauma (FAST) training for first-year resident physicians at a university hospital in Japan: A longitudinal, observational study
153. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
154. Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
155. Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
156. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: Differences according to histology and smoking status
157. Improvement in Surgical Outcomes Using 3-Dimensional Printed Models for Lateral Pelvic Lymph Node Dissection in Rectal Cancer.
158. Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor?
159. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma
160. FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
161. Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms
162. Multicentre Phase II Study of XELOX with Bevacizumab in Late-stage Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer: An ASCA Study
163. Impact of Body Weight Gain on the Incidence of Nonalcoholic Fatty Liver Disease in Nonobese Japanese Individuals
164. Focused Assessment with Sonography in Trauma (FAST) Training for First-Year Resident Physicians at a University Hospital in Japan: A Longitudinal, Observational Study
165. Risk factors for outlet obstruction after laparoscopic surgery and diverting ileostomy for rectal cancer
166. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
167. Interleukin (IL)‐17F and IL‐17E are related to fibrosis and vasculopathy in systemic sclerosis
168. Rationale and design of the EMPYREAN study
169. Rapid decrease of serum surfactant protein‐D levels predicts the reactivity of rituximab therapy in systemic sclerosis‐associated interstitial lung disease
170. Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose–Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data
171. Perampanel for Sporadic Amyotrophic Lateral Sclerosis (138)
172. Rationale and Design of the EMPYREAN Study: Investigation on the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity in Japanese Patients with Type 2 Diabetes
173. Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
174. Final results of multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with mCRC refractory to standard therapies (BiTS study).
175. Safety and Efficacy of Perampanel for Sporadic Amyotrophic Lateral Sclerosis: A Multicentre, Double-Blind, Randomised Phase 2 Trial
176. Clinical Significance of Anti-U1 Ribonucleoprotein Antibody in Anti-Topoisomerase I Antibody-Positive Systemic Sclerosis Patients: A Retrospective Observational Study
177. Measures for evaluating risk prediction models: a review
178. Is Pulse Pressure a Predictor of New-Onset Diabetes in High-Risk Hypertensive Patients?: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial
179. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis‐associated interstitial lung disease.
180. The domain structure of the EORTC QLQ-STO22 supported by Japanese validation data
181. A Randomized Phase II Trial of Preoperative Exercise to Reduce Operative Risk in Gastric Cancer Patients with Metabolic Syndrome: Adjuvant Exercise for General Elective Surgery (AEGES) Study Group
182. MOESM1 of Reference value for expiratory time constant calculated from the maximal expiratory flow-volume curve
183. Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer
184. Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003
185. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan ; 2nd report QOL survey
186. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring
187. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey
188. Association of blood mercury levels during pregnancy with infant birth size by blood selenium levels in the Japan Environment and Children's Study : A prospective birth cohort
189. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan ; 2nd report QOL survey
190. Factors influencing the number of retrieved lymph nodes after colorectal resection: a retrospective study from a single institute
191. Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al’ by Berkhout et al
192. Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory Biomarkers for Patients with Stage II/III Colon Cancer
193. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial
194. Impact of Residual Stenosis on the Angiographic Edge Restenosis of a Second-Generation Drug-Eluting Stent
195. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan; 2nd report QOL survey
196. Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin‑based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
197. Risk factors for paraaortic lymph-node recurrence in colorectal cancer
198. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring
199. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis
200. Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.